Quick Answer
Harmony Biosciences Holdings, Inc. reported Cash And Cash Equivalents At Carrying Value of $752.50 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +66.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $221.74 million | Q1 2021: $141.17 million | Q2 2021: $159.69 million | Q3 2021: $189.70 million | Q1 2022: $224.50 million | Q2 2022: $236.53 million | Q3 2022: $261.34 million | Q1 2023: $287.96 million | Q2 2023: $317.42 million | Q3 2023: $324.60 million | Q1 2024: $332.98 million | Q2 2024: $317.30 million | Q3 2024: $387.37 million | Q1 2025: $489.00 million | Q2 2025: $546.05 million | Q3 2025: $647.00 million.
- Over the full 7 years of available data (2019 to 2025), Harmony Biosciences Holdings, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 2,976.8%.
- Historical annual values: Fiscal year 2025: $752.50 million | Fiscal year 2024: $453.00 million | Fiscal year 2023: $311.66 million | Fiscal year 2022: $243.78 million | Fiscal year 2021: $234.31 million | Fiscal year 2020: $228.63 million | Fiscal year 2019: $24.46 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: